Immune checkpoint inhibitor-related myositis and myocarditis: diagnostic pitfalls and imaging contribution in a real-world, institutional case series.
Imaging
Immune-checkpoint-inhibitor
Immune-related-adverse-event
Myocarditis
Myositis
Journal
Journal of neurology
ISSN: 1432-1459
Titre abrégé: J Neurol
Pays: Germany
ID NLM: 0423161
Informations de publication
Date de publication:
23 Dec 2023
23 Dec 2023
Historique:
received:
03
10
2023
accepted:
22
11
2023
revised:
20
11
2023
medline:
23
12
2023
pubmed:
23
12
2023
entrez:
23
12
2023
Statut:
aheadofprint
Résumé
Immune checkpoint inhibitors (ICIs) are reshaping the prognosis of many cancers, but often cause immune-related adverse events (irAEs). Among neurological irAEs, myositis is the most frequently reported. Our aim is to describe clinical and non-clinical characteristics, treatment and outcome of all irMyositis (skeletal limb-girdle and/or ocular myositis) and irMyocarditis cases in our reference center. We retrospectively enrolled all irMyositis/irMyocarditis patients seen between 2018 and 2022. We reviewed demographics, clinical characteristics, biological, neurophysiological, imaging workup, treatment and outcome. We included 14 consecutive patients. The most frequent treatments were pembrolizumab (35%) or ipilimumab-nivolumab combination (35%). Limb-girdle, ocular (non-fluctuating palpebral ptosis and/or diplopia with or without ophthalmoparesis) and cardiac phenotypes were equally distributed, overlapping in 40% of cases. Ocular involvement was frequently misdiagnosed; review of brain MRIs disclosed initially missed signs of skeletal myositis in one patient and ocular myositis in 3. Seven patients had other co-existing irAEs. When performed, myography showed a myogenic pattern. CK was elevated in 8/15 patients, troponin-T in 12/12 and troponin-I in 7/9 tested patients. ICI were discontinued in all cases, with further immunosuppressive treatment in nine patients. In most cases, neurological and cardiological outcome was good at last follow-up. Myositis is a potentially severe irAE. Despite its heterogeneous presentation, some highly suggestive clinical symptoms, such as ocular involvement, or radiological signs should raise physicians' attention to avoid misdiagnosis. We thus recommend a multidisciplinary assessment (including complete neuromuscular evaluation) even in case of isolated myocarditis. Our series underlines the importance of an early diagnosis, since suspension of ICI and adequate treatment are usually associated with good functional outcome.
Sections du résumé
BACKGROUND
BACKGROUND
Immune checkpoint inhibitors (ICIs) are reshaping the prognosis of many cancers, but often cause immune-related adverse events (irAEs). Among neurological irAEs, myositis is the most frequently reported. Our aim is to describe clinical and non-clinical characteristics, treatment and outcome of all irMyositis (skeletal limb-girdle and/or ocular myositis) and irMyocarditis cases in our reference center.
METHODS
METHODS
We retrospectively enrolled all irMyositis/irMyocarditis patients seen between 2018 and 2022. We reviewed demographics, clinical characteristics, biological, neurophysiological, imaging workup, treatment and outcome.
RESULTS
RESULTS
We included 14 consecutive patients. The most frequent treatments were pembrolizumab (35%) or ipilimumab-nivolumab combination (35%). Limb-girdle, ocular (non-fluctuating palpebral ptosis and/or diplopia with or without ophthalmoparesis) and cardiac phenotypes were equally distributed, overlapping in 40% of cases. Ocular involvement was frequently misdiagnosed; review of brain MRIs disclosed initially missed signs of skeletal myositis in one patient and ocular myositis in 3. Seven patients had other co-existing irAEs. When performed, myography showed a myogenic pattern. CK was elevated in 8/15 patients, troponin-T in 12/12 and troponin-I in 7/9 tested patients. ICI were discontinued in all cases, with further immunosuppressive treatment in nine patients. In most cases, neurological and cardiological outcome was good at last follow-up.
CONCLUSION
CONCLUSIONS
Myositis is a potentially severe irAE. Despite its heterogeneous presentation, some highly suggestive clinical symptoms, such as ocular involvement, or radiological signs should raise physicians' attention to avoid misdiagnosis. We thus recommend a multidisciplinary assessment (including complete neuromuscular evaluation) even in case of isolated myocarditis. Our series underlines the importance of an early diagnosis, since suspension of ICI and adequate treatment are usually associated with good functional outcome.
Identifiants
pubmed: 38141128
doi: 10.1007/s00415-023-12134-x
pii: 10.1007/s00415-023-12134-x
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© 2023. The Author(s).
Références
Ribas A, Wolchok JD (1979) Cancer immunotherapy using checkpoint blockade. Science 2018(359):1350–1355. https://doi.org/10.1126/science.aar4060
doi: 10.1126/science.aar4060
Fife BT, Pauken KE (2011) The role of the PD-1 pathway in autoimmunity and peripheral tolerance. Ann N Y Acad Sci 1217:45–59. https://doi.org/10.1111/j.1749-6632.2010.05919.x
doi: 10.1111/j.1749-6632.2010.05919.x
pubmed: 21276005
Hodi FS, O’Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB et al (2010) Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 363:711–723. https://doi.org/10.1056/NEJMoa1003466
doi: 10.1056/NEJMoa1003466
pubmed: 20525992
pmcid: 3549297
Hargadon KM, Johnson CE, Williams CJ (2018) Immune checkpoint blockade therapy for cancer: an overview of FDA-approved immune checkpoint inhibitors. Int Immunopharmacol 62:29–39. https://doi.org/10.1016/j.intimp.2018.06.001
doi: 10.1016/j.intimp.2018.06.001
pubmed: 29990692
Postow MA, Sidlow R, Hellmann MD (2018) Immune-related adverse events associated with immune checkpoint blockade. N Engl J Med 378:158–168. https://doi.org/10.1056/NEJMra1703481
doi: 10.1056/NEJMra1703481
pubmed: 29320654
Haanen J, Obeid M, Spain L, Carbonnel F, Wang Y, Robert C et al (2022) Management of toxicities from immunotherapy: ESMO clinical practice guideline for diagnosis, treatment and follow-up ☆. Ann Oncol 33:1217–1238. https://doi.org/10.1016/j.annonc.2022.10.001
doi: 10.1016/j.annonc.2022.10.001
pubmed: 36270461
Martins F, Sykiotis GP, Maillard M, Fraga M, Ribi C, Kuntzer T et al (2019) New therapeutic perspectives to manage refractory immune checkpoint-related toxicities. Lancet Oncol 20:e54-64. https://doi.org/10.1016/S1470-2045(18)30828-3
doi: 10.1016/S1470-2045(18)30828-3
pubmed: 30614479
Martins F, Sofiya L, Sykiotis GP, Lamine F, Maillard M, Fraga M et al (2019) Adverse effects of immune-checkpoint inhibitors: epidemiology, management and surveillance. Nat Rev Clin Oncol 16:563–580. https://doi.org/10.1038/s41571-019-0218-0
doi: 10.1038/s41571-019-0218-0
pubmed: 31092901
Pan PC, Haggiagi A (2019) Neurologic immune-related adverse events associated with immune checkpoint inhibition. Curr Oncol Rep 21:108. https://doi.org/10.1007/s11912-019-0859-2
doi: 10.1007/s11912-019-0859-2
pubmed: 31776691
Marini A, Bernardini A, Gigli GL, Valente M, Muñiz-Castrillo S, Honnorat J et al (2021) Neurologic adverse events of immune checkpoint inhibitors. Neurology 96:754–766. https://doi.org/10.1212/WNL.0000000000011795
doi: 10.1212/WNL.0000000000011795
pubmed: 33653902
Dubey D, David WS, Reynolds KL, Chute DF, Clement NF, Cohen JV et al (2020) Severe neurological toxicity of immune checkpoint inhibitors: growing spectrum. Ann Neurol 87:659–669. https://doi.org/10.1002/ana.25708
doi: 10.1002/ana.25708
pubmed: 32086972
Lundberg IE, Tjärnlund A, Bottai M, Werth VP, Pilkington C, de Visser M et al (2017) European league against rheumatism/American college of rheumatology classification criteria for adult and juvenile idiopathic inflammatory myopathies and their major subgroups. Ann Rheum Dis 76:1955–1964. https://doi.org/10.1136/annrheumdis-2017-211468
doi: 10.1136/annrheumdis-2017-211468
pubmed: 29079590
van Swieten JC, Koudstaal PJ, Visser MC, Schouten HJ, van Gijn J (1988) Interobserver agreement for the assessment of handicap in stroke patients. Stroke 19:604–607. https://doi.org/10.1161/01.STR.19.5.604
doi: 10.1161/01.STR.19.5.604
pubmed: 3363593
Bonaca MP, Olenchock BA, Salem J-E, Wiviott SD, Ederhy S, Cohen A et al (2019) Myocarditis in the setting of cancer therapeutics. Circulation 140:80–91. https://doi.org/10.1161/CIRCULATIONAHA.118.034497
doi: 10.1161/CIRCULATIONAHA.118.034497
pubmed: 31390169
pmcid: 6779326
Touat M, Maisonobe T, Knauss S, Ben Hadj SO, Hervier B, Auré K et al (2018) Immune checkpoint inhibitor-related myositis and myocarditis in patients with cancer. Neurology 91:e985–e994. https://doi.org/10.1212/WNL.0000000000006124
doi: 10.1212/WNL.0000000000006124
pubmed: 30089619
Weill A, Delyon J, Descamps V, Deschamps L, Dinulescu M, Dupuy A et al (2021) Treatment strategies and safety of rechallenge in the setting of immune checkpoint inhibitors-related myositis: a national multicentre study. Rheumatology 60:5753–5764. https://doi.org/10.1093/rheumatology/keab249
doi: 10.1093/rheumatology/keab249
pubmed: 33725115
Escudier M, Cautela J, Malissen N, Ancedy Y, Orabona M, Pinto J et al (2017) Clinical features, management, and outcomes of immune checkpoint inhibitor-related cardiotoxicity. Circulation 136:2085–2087. https://doi.org/10.1161/CIRCULATIONAHA.117.030571
doi: 10.1161/CIRCULATIONAHA.117.030571
pubmed: 29158217
Moslehi JJ, Salem J-E, Sosman JA, Lebrun-Vignes B, Johnson DB (2018) Increased reporting of fatal immune checkpoint inhibitor-associated myocarditis. The Lancet 391:933. https://doi.org/10.1016/S0140-6736(18)30533-6
doi: 10.1016/S0140-6736(18)30533-6
Kimura T, Fukushima S, Miyashita A, Aoi J, Jinnin M, Kosaka T et al (2016) Myasthenic crisis and polymyositis induced by one dose of nivolumab. Cancer Sci 107:1055–1058. https://doi.org/10.1111/cas.12961
doi: 10.1111/cas.12961
pubmed: 27420474
pmcid: 4946722
Shirai T, Sano T, Kamijo F, Saito N, Miyake T, Kodaira M et al (2016) Acetylcholine receptor binding antibody-associated myasthenia gravis and rhabdomyolysis induced by nivolumab in a patient with melanoma. Jpn J Clin Oncol 46:86–88. https://doi.org/10.1093/jjco/hyv158
doi: 10.1093/jjco/hyv158
pubmed: 26491202
So H, Ikeguchi R, Kobayashi M, Suzuki M, Shimizu Y, Kitagawa K (2019) PD-1 inhibitor-associated severe myasthenia gravis with necrotizing myopathy and myocarditis. J Neurol Sci 399:97–100. https://doi.org/10.1016/j.jns.2019.02.023
doi: 10.1016/j.jns.2019.02.023
pubmed: 30798111
Lotan I, Hellmann MA, Wilf-Yarkoni A, Steiner I (2021) Exacerbation of myasthenia gravis following corticosteroid treatment: what is the evidence? A systematic review. J Neurol 268:4573–4586. https://doi.org/10.1007/s00415-020-10264-0
doi: 10.1007/s00415-020-10264-0
pubmed: 33064188
Wu WK, Broman KK, Brownie ER, Kauffmann RM (2017) Ipilimumab-induced Guillain-Barré syndrome presenting as dysautonomia: an unusual presentation of a rare complication of immunotherapy. J Immunother 40:196–199. https://doi.org/10.1097/CJI.0000000000000167
doi: 10.1097/CJI.0000000000000167
Doms J, Prior JO, Peters S, Obeid M (2020) Tocilizumab for refractory severe immune checkpoint inhibitor-associated myocarditis. Ann Oncol 31:1273–1275. https://doi.org/10.1016/j.annonc.2020.05.005
doi: 10.1016/j.annonc.2020.05.005
pubmed: 32425357
Palaskas N, Lopez-Mattei J, Durand JB, Iliescu C, Deswal A (2020) Immune checkpoint inhibitor myocarditis: pathophysiological characteristics, diagnosis, and treatment. J Am Heart Assoc. https://doi.org/10.1161/JAHA.119.013757
doi: 10.1161/JAHA.119.013757
pubmed: 31960755
pmcid: 7033840
Shelly S, Triplett JD, Pinto MV, Milone M, Diehn FE, Zekeridou A et al (2020) Immune checkpoint inhibitor-associated myopathy: a clinicoseropathologically distinct myopathy. Brain Commun. https://doi.org/10.1093/braincomms/fcaa181
doi: 10.1093/braincomms/fcaa181
pubmed: 33364599
pmcid: 7749792
Boughdad S, Latifyan S, Fenwick C, Bouchaab H, Suffiotti M, Moslehi JJ et al (2021)
doi: 10.1136/jitc-2021-003594
pubmed: 34686542
pmcid: 8543755
Lapa C, Reiter T, Li X, Werner RA, Samnick S, Jahns R et al (2015) Imaging of myocardial inflammation with somatostatin receptor based PET/CT—a comparison to cardiac MRI. Int J Cardiol 194:44–49. https://doi.org/10.1016/j.ijcard.2015.05.073
doi: 10.1016/j.ijcard.2015.05.073
pubmed: 26005805
Martins F, Obeid M (2020) Personalized treatment of immune-related adverse events—balance is required. Nat Rev Clin Oncol 17:517–517. https://doi.org/10.1038/s41571-020-0400-4
doi: 10.1038/s41571-020-0400-4
pubmed: 32546733